Wei Ding

1.7k citations
91 papers · 1.2k indexed · h-index 21

Impact in

    • Cancer-related molecular mechanisms research
    • MicroRNA in disease regulation
  • Urology top 10%

Papers in

Wei Ding

86 papers receiving 1.2k citations

Peers

Wei Ding
Comparison fields: 5 of 120
  • Cancer Research 229
  • Urology 56
  • Oncology 195
  • Hepatology 55
  • Molecular Biology 451
Replace Yating Yang with:
Yating Yang China
Jung‐Mo Ahn United States
Rafał Czajkowski Poland
Xiang Chen China
Hisham F. Bahmad United States
Quan Tian China
Weijun Wu China
Taku Yamamoto Japan
Sukyung Woo United States
Wei Ding relative to Yating Yang China Yating Yang's profile →
Citations per field
00.5×2.6×
Yating Yang · 1×
Citations per year

Countries citing papers authored by Wei Ding

Since Specialization
Citations

This map shows the geographic impact of Wei Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Ding more than expected).

Fields of papers citing papers by Wei Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Ding. The network helps show where Wei Ding may publish in the future.

Co-authors

The 25 scholars most cited alongside Wei Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wei Ding Line = papers co-authored together Wei Ding links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 91 papers — load more, or switch the sort, to bring in the rest.

#Work
1 201782
2 201879
3 201978
4 201964
5 201933
6 201731
7 202030
8 202130
9 201929
10 200328
11 200828
12 202026
13 202325
14 202024
15 201924
16 201423
17 201723
18 201223
19 202222
20 202122

About Wei Ding

Wei Ding is a scholar working on Cancer Research, Organic Chemistry, Biochemistry, Pulmonary and Respiratory Medicine and Oncology, having authored 91 papers that have together received 1.2k indexed citations. Recurring topics across this work include RNA modifications and cancer (12 papers), Luminescence and Fluorescent Materials (9 papers), Cancer-related molecular mechanisms research (8 papers), Supramolecular Self-Assembly in Materials (6 papers), Carbohydrate Chemistry and Synthesis (6 papers), Ferroptosis and cancer prognosis (6 papers), RNA Research and Splicing (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Cancer Research (229 citations), Urology (56 citations), Oncology (195 citations), Hepatology (55 citations) and Molecular Biology (451 citations). Wei Ding has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Yulin Tan, Wenbo Xue, Xuezhong Xu, Yibo Wang, Anyang Wei, Lei Jin, Jianguo Du, Xiao‐Xin Shi, Qian Yan and Xia Lü. Their work appears in journals such as Medicine, Tetrahedron Asymmetry, Chinese Journal of Chemistry, Journal of Oncology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026